Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)

0
189

Funding Opportunity ID: 325600
Opportunity Number: RFA-HG-20-015
Opportunity Title: Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.172
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Mar 19, 2020
Close Date: Jun 24, 2022
Last Updated Date: Mar 19, 2020
Award Ceiling: $0
Award Floor: $0
Estimated Total Program Funding:
Expected Number of Awards:
Description: This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.
Version: 1





Visit the Official Webpage For More Details on Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)